Skip to main content

One Wales infliximab

 

Status: One Wales interim decision

Using the agreed starting and stopping criteria, infliximab can be made available within NHS Wales for the treatment of immune checkpoint inhibitor induced grade 3-4 enterocolitis, where symptoms have not responded to first line immunosuppression with corticosteroids.

Infliximab should be prescribed on the basis of lowest acquisition cost.

The risks and benefits of the off-label use of infliximab for this indication should be clearly stated and discussed with the patient to allow informed consent. Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.

This advice will be reviewed after 12 months or earlier if new evidence becomes available.

 One Wales Interim Decision with decision rationale and start stop criteria Infliximab for ICI enterocolitis. OW21. 2022 (PDF, 87Kb)
 Evidence Status Report. Infliximab for ICI enterocolitis. OW21. 2022 (PDF, 164Kb)

Medicine details

Medicine name One Wales infliximab
Formulation powder for solution for infusion
Reference number OW21
Indication

Treatment of immune checkpoint inhibitor induced grade 3-4 enterocolitis, where symptoms have not responded to first line immunosuppression with corticosteroids

Company various
BNF chapter Gastro-intestinal system
Submission type One Wales
Status One Wales interim decision
Advice number OW21
Date of issue 02/02/2023
Follow AWTTC: